D-0001-2018 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0001-2018 was initiated by Pfizer Inc. on Jul 12, 2017 and is designated Class III. Reason for recall: CGMP Deviations: Firm failed to control impurity for color change at the API stage. The recall status is terminated (terminated Jul 16, 2020). Affected quantity: 32,276 10 mL vials.

Recall details

Product Type
Drugs
Report Date
Oct 11, 2017
Initiation Date
Jul 12, 2017
Termination Date
Jul 16, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
32,276 10 mL vials

Product description

Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.

Reason for recall

CGMP Deviations: Firm failed to control impurity for color change at the API stage.

Distribution pattern

Nationwide

Code information

Lot: 51275DD; Exp. 09/01/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0001-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0001-2018. Report a data issue: hello@regdatalab.com.